Compare Adobe Systems Inc (ADBE) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Incyte Corporation — how do they compare? Adobe Systems Inc trades at $220.48 (market cap $88.06B), while Incyte Corporation trades at $117.33 (market cap $23.10B). The key difference: Adobe Systems Inc is far larger — about 3.8× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | INCY | |
|---|---|---|
Market Cap | $88.06B | $23.10B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $118.05 |
52-Week Low | $193.41 | $67.38 |
Enterprise Value | $89.50B | $19.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) trades at $220.94, up 1.32% with strong fundamentals including 29.99% net margin and consistent earnings beats. Technical indicators show bullish momentum with support at $218 and resistance at $228. Recent news highlights institutional buying despite AI competition concerns, while cash flow remains robust at $10.03B from operations in 2025.
Outlook remains positive with a $246.75 analyst target, though risks include AI disruption and CEO transition. Valuation appears attractive with P/E of 12.67, supporting a buy case for long-term growth investors amid near-term volatility.
Incyte (INCY) trades at $118.05, up 1.02% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion and a robust net margin of 26.71%. Recent catalysts include the acquisition of Vega Therapeutics and positive regulatory updates for Opzelura in Europe, supporting momentum.
The outlook remains positive given earnings beats, expanding product portfolio, and analyst consensus leaning buy. Key risks include reliance on key drugs, regulatory hurdles, and competitive pressures. The stock trades above the consensus price target of $109.14, suggesting near-term consolidation potential amid overbought RSI levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
